Health & Wellness

National Leader in Pancreatic Cancer Opens Unique Clinical Trials in Morristown

1d7c00696d2c42e447aa_55b2b65b12253ca923d1_download.jpg
1d7c00696d2c42e447aa_55b2b65b12253ca923d1_download.jpg

Dr. Angela Alistar is national principal investigator for first-in-class drug CPI-613

Morristown, NJ – Atlantic Health System is now enrolling patients in four pancreatic cancer clinical trials.  Angela Alistar, MD, a nationally known expert on pancreatic cancer, is serving as national Principal Investigator (PI) on the first trial and as local PI on three other trials.  In addition, Dr. Alistar will serve as a national and local PI on three additional clinical studies open to enrollment later this year.

“We are fortunate to be able to offer these studies to people with this difficult-to-treat, aggressive cancer,” said Dr. Alistar, who serves as director of GI medical oncology at the Carol G. Simon Cancer Center of Morristown Medical Center, Atlantic Health System. “Our pancreatic cancer program is unique, and our ability to provide access to these clinical trials is one important aspect of our uniqueness. New and more effective treatments are desperately needed.”

Sign Up for E-News

Five-year survival rates for pancreatic cancer are low, even when caught early.  In 2016, pancreatic cancer moved from the fourth leading cause of cancer-related deaths in the U.S. to the third, surpassing breast cancer.

“Dr. Alistar is a leading figure in GI cancer research and treatment, and she has significantly enhanced our ability to care for our patients,” said Eric Whitman, MD, medical director, Atlantic Health System Cancer Care.  “She has expanded Atlantic Health System’s ability to offer participation in clinical trials for pancreatic cancer and other gastrointestinal malignancies, as well as the latest treatments, such as those that work with patients’ immune systems to destroy cancer cells.” 

Pancreatic cancer studies that are currently enrolling patients include:

  • Phase 1 Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer.  This is a single arm, open-label study of CPI-613, a first-in-class drug with a unique mode of action, in combination with chemotherapeutic agents gemcitabine and nab-paclitaxel.  The study, which is funded by Raphael Pharmaceuticals, Inc., is designed for patients with locally advanced or metastatic pancreatic cancer never treated with systemic chemotherapy. Atlantic Health System is the only program in the world to offer this promising study.  Dr. Alistar led previous studies of this promising drug with pancreatic cancer activity, which have been presented at major international scientific meetings and published in The Lancet Oncology.NCT03435289
  • Phase 2 Study of the Antioxidant BPM31510 (Ubidecarenone, or CoQ10)  Nanosuspension Injection Administered Intravenously With or Without Gemcitabine as 2nd/3rd Line Therapy in Advanced Pancreatic Cancer Patients. This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered as a 144-hour continuous intravenous infusion by itself or in combination with gemcitabine in advanced pancreatic cancer patients as a 2nd / 3rd line therapy. The study is sponsored by Berg LLC and is open at seven total sites in the U.S. Atlantic Health System is the only study site in New Jersey and New YorkNCT02650804 
  • An SU2C Catalyst® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response. Chemotherapy regimens for pancreatic cancer can now stabilize a patient's cancer and/or place some patients in remission or partial remission. The challenge now is to find options for maintenance therapies that will improve survival and allow continued benefits with minimal toxicities and inconvenience to patients. This study will determine the effects of immunotherapy as one possible maintenance regimen. The study is being conducted to determine the effects that pembrolizumab with or without the addition of paricalcitol may have on pancreatic cancer. Half of the patients will be randomized to receive pembrolizumab (KeytrudaÒ, a monoclonal antibody) plus paricalcitol (synthetic Vitamin D) and half to receive pembrolizumab plus placebo.  This study is sponsored by The Translational Genomics Research Institute. Atlantic Health System’s Morristown Medical Center is the only center on the East Coast that has this study open. NCT03331562
  • Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas. The purpose of this study is to determine the best sequence of   chemotherapy and chemoradiotherapy prior to surgery. This study is sponsored by Alliance and is open nationwide. NCT02839343  

Each study has specific criteria for participation.

To learn more about these studies, please call the Atlantic Center for Research at

(973) 971-6608, contact Dr. Alistar’s office, (973) 971-7960, or visit www.atlantichealth.org/research.

 

About Atlantic Health System

Atlantic Health System, headquartered in Morristown, N.J., is an integrated health care delivery system powered by a workforce of 16,000 team members dedicated to building healthier communities. The system is comprised of 350 sites of care, including six hospitals: Morristown Medical Center, Overlook Medical Center, Newton Medical Center, Chilton Medical Center, Hackettstown Medical Center and Goryeb Children’s Hospital. Atlantic Health System also supports communities through Atlantic Medical Group, Atlantic Rehabilitation, Atlantic Home Care and Hospice, and its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System sponsors the Atlantic Accountable Care Organization, one of the larger ACOs in the nation, and Optimus Healthcare Partners. 

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Parsippany

Kessler Foundation Seeks Volunteers for Important Breast Cancer Study

July 13, 2018

Researchers at Kessler Foundation in West Orange, NJ are studying new ways of combating breast cancer-related weakness & fatigue. These symptoms can diminish quality of life & often last long after treatment has ended. If you are a woman aged 40-75, who was diagnosed with breast cancer within the past 10 years*, you may qualify for this important research study.

We are ...

Parsippany BOYS & GIRLS INVITED TO FREE SUMMER ADVENTURE NIGHTS

STANHOPE, NJ – July 5, 2018– Time for the whole family to experience adventure this summer!  Have some free summer evenings and ready for a summer evening of family fun?!  Families are invited to attend any of four Family Adventure Nights at Camp Wheeler or Watchung Day Camp at no cost. Program consists of archery shooting, STEM activities, BB shooting, aquatics, campfire, ...

Take the 2018 TAPinto Reader Survey

How often do you read TAPinto?  Have you downloaded the TAPinto APP?  These are a few of the questions for readers in our 2018 TAPinto Reader Survey.

We want to hear from you!

The survey will take less than five minutes to complete and will help TAPinto better serve you. 

Take the 2018 TAPinto Reader Survey.

Thank you.  We appreciate your support and ...

Paul Boudreau, Morris County Chamber president, to retire and replacement search begins

Jack Miller, chairman of the board of directors of Morris County Chamber of Commerce, has announced that Paul Boudreau, the chamber's president, will retire effective Dec. 31. The chamber board has retained a search firm and formed a Search Committee to secure Boudreau's replacement.

 

Boudreau has been president of the chamber since 2008. During the last 10 years he led the ...

Teva Pharmaceuticals Bringing Nearly 1,000 Jobs, New Headquarters to Parsippany

PARSIPPANY – Today, Teva Pharmaceuticals announced that they will be moving their North American headquarters to Parsippany.  This move is anticipated to support well over 800 new jobs with a median annual wage of $128,073.  Teva Pharmaceuticals will be expanding their current footprint in Parsippany to accommodate this growth.  The current site will now house 350,000 square ...

Free A Cappella Singing Lessons Offered by Women’s Chorus

The Hickory Tree Chorus chapter of Sweet Adelines International invites women singers to register for its free “Sing A Cappella Series” of vocal workshops. Women will learn to sing chord-ringing, fun-filled, four-part a cappella music, Wednesdays, 7:15pm, August 1st and 8th at The Shrine of St Joseph, 1050 Long Hill Road, Stirling, NJ.  

Each week guests will participate in ...

Lisa McCormick comments after Gov. Murphy caves on budget demands

July 8, 2018

To the Editor,

Gov. Philip D. Murphy bowed to pressure from Democratic lawmakers rather than force a government shutdown over his demand for millionaires tax like the five measures vetoed by former Republican Gov Chris Christie.

At 7:30 pm on June 30, the last day of the fiscal year, Murphy held a news conference with Assembly Speaker Craig Coughlin and Senate President  ...

Millionaires and Mudslinging

To the Editor,

I was promised that New Jersey Democrats would enact a millionaires tax that extended the one we had when Jon Corzine was governor but I knew they would never have let that lapse if they wanted anything other than a political football.

Gov Chris Christie was sent a bill to veto five times because it made him look bad. 

Assembly Democrats don't really care ...

Concerned Resident Speaks Out

Dear Editor,

As a concerned mother, I feel impelled to speak out on last week’s revelations regarding a prominent Parsippany public figure.

After reading Mr. Tom DeLorenzo’s letter to the editor, I realized how important it is not to remain silent.  I was completely unaware the severity of the content until I had been forwarded some of the actual screenshots from ...